Cryoprecipitate Dosing and Administration Guidelines

Target Fibrinogen Levels by Clinical Context

In major (non‑obstetric) hemorrhage, maintain fibrinogen > 1.5 g/L. 1
In obstetric hemorrhage, maintain fibrinogen > 2.0 g/L. 2
In patients with liver disease and active bleeding, maintain fibrinogen > 1.0 g/L. 2

Cryoprecipitate is indicated when fibrinogen is < 80–100 mg/dL (0.8–1.0 g/L) together with excessive microvascular bleeding. 3
It is rarely indicated when fibrinogen is > 150 mg/dL (1.5 g/L) in non‑pregnant patients. 3
In massively transfused patients, give cryoprecipitate empirically if fibrinogen cannot be measured promptly. 3

Each individual cryoprecipitate unit contains approximately 400–450 mg of fibrinogen. 1
A pooled unit (5 individual units) provides roughly 2 g of fibrinogen. (no citation – omitted)

Store cryoprecipitate at ‑25 °C; after thawing, keep at ambient temperature for up to 4 hours. 1
Do not re‑refrigerate the product after thawing. 1
Use a standard blood‑giving set equipped with a 170–200 µm filter. 1
Infuse at 10–20 mL/kg/h (approximately 30–60 minutes for one pooled unit). 4

Subsequent doses should be guided by viscoelastic (ROTEM/TEG) monitoring together with laboratory fibrinogen measurements. 5

Verify fibrinogen ≥ 50 mg/dL (preferably ≥ 100 mg/dL) before transfusion. 6
Ensure platelet count ≥ 50 × 10⁹/L (preferably ≥ 100 × 10⁹/L). 6
Correct acidosis to pH ≥ 7.2. 6
Restore body temperature toward normothermia; hypothermia does not contraindicate use. 6

All doses are based on expert consensus. 6

The CRYOSTATS‑2 randomized trial (2023) showed that early empiric administration of three pooled units (≈6 g fibrinogen) did not reduce 28‑day mortality compared with standard care (25.3 % vs 26.1 %; OR 0.96, 95 % CI 0.75–1.23). This suggests that fibrinogen‑guided, targeted transfusion is superior to empiric dosing. 7

For adults with significant bleeding and hypofibrinogenemia, an initial dose of 50 mg/kg (≈ 15–20 units or 2 pooled units in a 70 kg adult) is recommended to achieve a target fibrinogen level of 1.5–2.0 g/L. 8
One pooled unit of cryoprecipitate typically contains 5 units and provides ≈ 2 g of fibrinogen. 9
Two units per 10 kg body weight raise plasma fibrinogen concentration by roughly 1 g/L. 10, 11
Each individual unit contains 400–450 mg of fibrinogen. 9
The fibrinogen concentration in cryoprecipitate ranges from 15–17 g/L. 10
During major hemorrhage, maintain fibrinogen > 1.5–2.0 g/L. 8
In obstetric hemorrhage, maintain fibrinogen > 2.0 g/L. 12, 9
Cryoprecipitate is indicated when fibrinogen is < 80–100 mg/dL together with excessive microvascular bleeding. 13, 14
Transfusion is rarely indicated if fibrinogen is > 150 mg/dL in non‑pregnant patients. 14

For children, a volume‑based dose of 5–10 mL/kg of cryoprecipitate is recommended. 12, 15
Blood components for pediatric patients should be prescribed by volume rather than by unit count. 12, 15
Neonates require components specifically prepared for neonatal use, including CMV‑negative products. 12

Cardiac surgery: an initial dose equivalent to 3–4 g fibrinogen (≈ 2 pooled units) is advised. 8
Liver disease with bleeding: aim to keep fibrinogen > 1.0 g/L. 9

Cryoprecipitate contains not only fibrinogen but also von Willebrand factor, factor VIII, factor XIII, and fibronectin. 10, 11
This multi‑component composition may provide functional hemostatic advantages beyond isolated fibrinogen replacement. 11

Use a standard blood‑giving set equipped with a 170–200 µm filter. 9
After thawing, cryoprecipitate may be kept at ambient temperature for up to 4 hours; it should not be re‑refrigerated. 9
ABO‑compatible pooling of cryoprecipitate is required before transfusion in adults. 10

Repeat dosing should be guided by thrombelastometric (viscoelastic) monitoring together with laboratory fibrinogen measurements. 8
Laboratory Clauss fibrinogen assays can overestimate fibrinogen when hydroxyethyl starch is present. 16
Point‑of‑care viscoelastic testing (e.g., thrombelastometry) is preferred during active hemorrhage when conventional laboratory turnaround is too slow. 12

Cryoprecipitate is recommended when fibrinogen falls below 1.0 g/L (100 mg/dL) in a patient with active bleeding from snakebite‑induced venom‑induced consumption coagulopathy (VICC); the initial dose is 15–20 units (≈3–4 g fibrinogen) and therapy should be guided by laboratory fibrinogen levels and viscoelastic monitoring. 17
A fibrinogen level < 0.8–1.0 g/L (80–100 mg/dL) in the presence of excessive microvascular bleeding warrants cryoprecipitate administration. [17][18]
In non‑pregnant patients, transfusion is rarely indicated when fibrinogen > 1.5 g/L (150 mg/dL). [17][18]
For massively bleeding patients in whom fibrinogen cannot be measured promptly, an empirical dose of cryoprecipitate may be given. 17

The recommended initial regimen is 15–20 units (≈3–4 g fibrinogen) or two pooled units for a 70‑kg adult. 19
Two pooled units per 10 kg body weight raise plasma fibrinogen concentration by roughly 1 g/L. 20

Cryoprecipitate should be infused using a standard blood‑giving set equipped with a 170–200 µm filter. 21
After thawing, the product may be kept at ambient temperature for up to 4 hours; it must not be re‑refrigerated. 21
ABO‑compatible pooling must be confirmed before transfusion. 21

Subsequent dosing should be directed by viscoelastic monitoring (ROTEM/TEG) together with laboratory fibrinogen measurements. 19

The CRYOSTAT‑2 randomized trial found that early empiric administration of cryoprecipitate (6 g fibrinogen) did not reduce 28‑day mortality compared with standard care (25.3 % vs 26.1 %; OR 0.96, 95 % CI 0.75–1.23). 22

Fibrinogen concentrate offers a predictable 20 g/L concentration and includes viral inactivation, making it an alternative to cryoprecipitate. [21][20]
Each gram of fibrinogen concentrate increases the Clauss fibrinogen level by 0.2–0.3 g/L. 20
Cryoprecipitate also contains additional hemostatic proteins (von Willebrand factor, factor VIII, factor XIII, fibronectin) that may provide functional advantages beyond isolated fibrinogen replacement. 20